Literature DB >> 3050448

The metabolic environment of cancer.

J M Argilés1, J Azcón-Bieto.   

Abstract

The tumor cell has a very distinctive metabolism. It acts as a metabolic trap for host nutrients thus taking vital compounds for the metabolism of the host. Depending on the particular tumor growing pattern, cancer cells use preferentially glucose or amino acids for their energetic or biosynthetic needs. Lipids, fatty acids in particular, can also be taken up by the tumor cell. In addition, it can also release some compounds into the host circulation which are not normally produced by the original cell before neoplastic transformation. Some of these compounds affect the metabolism of the host in an unfavorable way since they can oppose the host's metabolic responses, which sustain homeostasis. The final product is that the metabolic machinery of these cells allows them to grow continuously in an uncontrolled manner. The consequences of tumor invasion on the host's metabolism are varied. They have, however, one thing in common: the reduction of the metabolic efficiency of the host. Muscular protein depletion, increased gluconeogenesis, uncoupling of oxidative phosphorylation constitute the main metabolic responses of the host as a result of tumor invasion. The net result of all these metabolic changes is profound energy imbalance which normally ends with cachexia and, eventually, death.

Entities:  

Mesh:

Year:  1988        PMID: 3050448     DOI: 10.1007/BF00225648

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  98 in total

Review 1.  Growth factors and cancer.

Authors:  A S Goustin; E B Leof; G D Shipley; H L Moses
Journal:  Cancer Res       Date:  1986-03       Impact factor: 12.701

2.  Beta-hydroxybutyrate dehydrogenase activity in liver and liver tumors.

Authors:  K Ohe; H P Morris; S Weinhouse
Journal:  Cancer Res       Date:  1967-08       Impact factor: 12.701

3.  Amino acid, glucose, and lactic acid utilization in vivo by rat tumors.

Authors:  L A Sauer; J W Stayman; R T Dauchy
Journal:  Cancer Res       Date:  1982-10       Impact factor: 12.701

Review 4.  Fat metabolism and cancer.

Authors:  P F McAndrew
Journal:  Surg Clin North Am       Date:  1986-10       Impact factor: 2.741

5.  Enzymes of serine metabolism in normal, developing and neoplastic rat tissues.

Authors:  K Snell
Journal:  Adv Enzyme Regul       Date:  1984

6.  Gluconeogenesis from alanine in patients with progressive malignant disease.

Authors:  C Waterhouse; N Jeanpretre; J Keilson
Journal:  Cancer Res       Date:  1979-06       Impact factor: 12.701

7.  Cachexia of malignancy: potential role of insulin in nutritional management.

Authors:  P S Schein; D Kisner; D Haller; M Blecher; M Hamosh
Journal:  Cancer       Date:  1979-05       Impact factor: 6.860

8.  Circulating triacylglycerols, lipoproteins, and tissue lipoprotein lipase activities in rat mothers and offspring during the perinatal period: effect of postmaturity.

Authors:  I Ramírez; M Llobera; E Herrera
Journal:  Metabolism       Date:  1983-04       Impact factor: 8.694

9.  Carbohydrate metabolism in cancer cachexia.

Authors:  C P Holroyde; G A Reichard
Journal:  Cancer Treat Rep       Date:  1981

10.  Epinephrine activation of phosphofructokinase in perfused rat heart independent of changes in effector concentrations.

Authors:  M G Clark; G S Patten
Journal:  J Biol Chem       Date:  1981-01-10       Impact factor: 5.157

View more
  19 in total

1.  Proteomics analysis of H-RAS-mediated oncogenic transformation in a genetically defined human ovarian cancer model.

Authors:  Travis Young; Fang Mei; Jinsong Liu; Robert C Bast; Alexander Kurosky; Xiaodong Cheng
Journal:  Oncogene       Date:  2005-09-08       Impact factor: 9.867

Review 2.  Relevance of glutamine metabolism to tumor cell growth.

Authors:  M A Medina; F Sánchez-Jiménez; J Márquez; A Rodríguez Quesada; I Núñez de Castro
Journal:  Mol Cell Biochem       Date:  1992-07-06       Impact factor: 3.396

3.  The effects of tumour necrosis factor-alpha (cachectin) and tumour growth on hepatic amino acid utilization in the rat.

Authors:  J M Argilés; F J López-Soriano
Journal:  Biochem J       Date:  1990-02-15       Impact factor: 3.857

4.  Comparative effects of tumour necrosis factor-alpha (cachectin), interleukin-1-beta and tumour growth on amino acid metabolism in the rat in vivo. Absorption and tissue uptake of alpha-amino[1-14C]isobutyrate.

Authors:  J M Argilés; F J López-Soriano; D Wiggins; D H Williamson
Journal:  Biochem J       Date:  1989-07-15       Impact factor: 3.857

5.  The oxidation of leucine in tumour-bearing rats.

Authors:  J M Argilés; F J López-Soriano
Journal:  Biochem J       Date:  1990-05-15       Impact factor: 3.857

6.  Metabolomics in bladder cancer: a systematic review.

Authors:  Yidong Cheng; Xiao Yang; Xiaheng Deng; Xiaolei Zhang; Pengchao Li; Jun Tao; Chao Qin; Jifu Wei; Qiang Lu
Journal:  Int J Clin Exp Med       Date:  2015-07-15

7.  Lipid metabolism in rats bearing the Yoshida AH-130 ascites hepatoma.

Authors:  J López-Soriano; J M Argilés; F J López-Soriano
Journal:  Mol Cell Biochem       Date:  1996-12-06       Impact factor: 3.396

8.  Amino acid uptake in skeletal muscle of rats bearing the Yoshida AH-130 ascites hepatoma.

Authors:  C García-Martínez; F J López-Soriano; J M Argilés
Journal:  Mol Cell Biochem       Date:  1995-07-05       Impact factor: 3.396

9.  Exploring Metabolic Profile Differences between Colorectal Polyp Patients and Controls Using Seemingly Unrelated Regression.

Authors:  Chen Chen; Lingli Deng; Siwei Wei; G A Nagana Gowda; Haiwei Gu; Elena G Chiorean; Mohammad Abu Zaid; Marietta L Harrison; Joseph F Pekny; Patrick J Loehrer; Dabao Zhang; Min Zhang; Daniel Raftery
Journal:  J Proteome Res       Date:  2015-05-13       Impact factor: 4.466

10.  Modulatory effect of Ganoderma lucidum on expression of xenobiotic enzymes, oxidant-antioxidant and hormonal status in 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats.

Authors:  Krishnamoorthy Deepalakshmi; Sankaran Mirunalini
Journal:  Pharmacogn Mag       Date:  2013-04       Impact factor: 1.085

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.